VivoSim Labs, Inc. reported stockholders’ equity of $(1.1 million), potentially risking its Nasdaq listing. The company has 45 calendar days to submit a compliance plan, impacting investor confidence significantly.

[CTA: Join our daily market newsletter]

Key Highlights

  • VivoSim Labs reported stockholders’ equity of $(1,099,000) as of March 31, 2026.
  • The company has until September 3, 2026, to present a plan to regain compliance with Nasdaq Rule 5550.
  • Shares of VivoSim Labs have declined 77.7% year-to-date.

Nasdaq Compliance Threatened

VivoSim Labs, Inc. (NASDAQ: VIVS) has received a notice from Nasdaq indicating it no longer meets the required minimum stockholders' equity threshold. The report shows a deficit of $(1,099,000) as of March 31, 2026, falling short of the $2,500,000 requisite set by Nasdaq Rule 5550. The company now faces a critical timeframe to address this issue, having until September 3, 2026, to submit a detailed compliance plan.

The potential delisting looms large, especially given the company's stock has plummeted 77.7% this year, signaling significant investor concern.

Financial Mechanics Under Scrutiny

In its recent annual report, VivoSim Labs highlighted notable financial activities that could impact its compliance trajectory. During July 2026, the company received a $5.0 million milestone payment from Eli Lilly and Company for achieving a specific development milestone in its FXR Asset. The company exercised approximately 3,370,827 of available warrants between July 15 and July 17, which contributed approximately $5.1 million to stockholders’ equity.

While these activities add some liquidity, they are insufficient to meet Nasdaq's equity requirements, emphasizing the precarious nature of the company's current financial situation.

Declining Market Performance

Shares of VivoSim Labs have seen significant declines, with reports indicating troubling trends in value. The company's performance raises intense scrutiny from investors and analysts alike, as it struggles to maintain its standing on Nasdaq. The dwindling equity figures and related compliance issues signal significant challenges ahead for VivoSim.

Investors are likely weighing the risks associated with a potential delisting against the company’s ongoing financial struggles.

Next Steps for Investors

VivoSim Labs has a important deadline approaching, with the requirement to submit a compliance plan to Nasdaq by September 3, 2026. Failure to create an acceptable plan could lead to a lost appeal before a Nasdaq hearings panel. Investors should closely monitor updates regarding this compliance submission and the resulting impact on stock performance.

Given the ongoing volatility, the situation remains fluid, and significant strategic pivots could be necessary to reassure stakeholders and stabilize market confidence.

Peers Moving on This News

  • Bone Biologics Corp (BBLG) down 0.9%
  • Calidi Biotherapeutics Inc (CLDI) down 4.0%
  • Shuttle Pharmaceuticals Holdings Inc (SHPH) down 2.1%

Analysis based on the Form 8-K filed 24 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.